Meshconomy

Geneus SAS (registered as Geneus Biotech SAS; brand Geneus®)

LiquidBlackout / LiquidVector biodefense and biointrusion systems, restricted to authorised government buyers.

Paris, France

1-10

Acquired by IPSC Holdings B.V. 15 Jun 2023 Source

Latest event found: 7 Jun 2026 · 4 months ago

Vitality Radar

Insufficient evidence

Current

6M History

Industry

Updated 10 days ago

Pillar Analysis

Presence

The analyst’s view of digital footprint. Shown for context; not part of the score.

Business

Dated funding, customer wins, partnerships and acquisitions made, less down rounds, litigation and regulatory action.

insufficient evidence

Innovation

Dated product launches and regulatory clearances, less products retired.

Pulse

Direction: dated events in the last 90 days against the 90 before. 50 is flat.

Capacity

Dated hiring, leadership hires, expansion and certifications, less layoffs, departures and closures.

insufficient evidence

Strategic Assessment

Strategic Vector

Geneus appears positioned as a very small Paris-based biotechnology and materials-science venture focused on biological research, biodegradable medical materials, and potentially bio-based textile applications. Public evidence indicates limited current commercial activity and no clearly documented recent growth, partnership, funding, or ownership event.

Efficiency Ratio

The company shows a lean resource profile, but publicly observable output is too limited to demonstrate strong resource-to-market efficiency.

Evidence Signals

Product Launch LOW IMPACT LOW CONF 7 Jun 2026

The Geneus website presented the Geneus brand and materials-science positioning, with Paris identified as the company location.

View source Paris, France

Background · older than 12 months

Expansion MEDIUM IMPACT MEDIUM CONF 15 Jun 2023

Geneus Biotech SAS was established in Paris with a stated purpose covering biological research, production, and development of medical and biodegradable materials.

View source Paris, France

Ownership Change MEDIUM IMPACT MEDIUM CONF 15 Jun 2023

IPSC Holdings B.V. was listed as president when Geneus Biotech SAS was incorporated.

View source Paris, France

About: Geneus SAS, registered as Geneus Biotech SAS in the 7th arrondissement of Paris with EUR 50,000 share capital, markets LiquidBlackout and LiquidVector as a biodefense and biointrusion system, available only to authorised government, military and law-enforcement customers subject to export-control screening. Everything known comes from the company's own pages; the gap between the scale of the claim and the size of the entity is the reason to verify before relying on this record.
Relevancy: Its own product page carries a named, dedicated defense product line (LiquidBlackout / LiquidVector, a 'biodefense/biointrusion system') with access restricted to authorised government/military/law-enforcement customers including export-control screening. More than an application-list mention (not a pure EPIGAP case) but resting exclusively on self-presentation. Anchor A2 (self-declaration only). Classified C12-08.
Tags: #Biodefense #CBRN #Biointrusion #LiquidBlackout #ExportControlled #GatedProduct #France

Suggest an edit